Company Encyclopedia
View More
name
89Bio
ETNB.US
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. The company was founded in 2018 and is headquartered in San Francisco, California.
1.912 T
ETNB.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Top Pharmaceutical Stocks To Add to Your Watchlist - November 6th

    Eli Lilly, Pfizer, Novo Nordisk, 89BIO, McKesson, AbbVie, and Teva Pharmaceutical Industries are highlighted as top pharmaceutical stocks to watch, according to MarketBeat. These companies are involved in the research, development, and sale of pharmaceuticals, offering growth potential but also facing risks from clinical trials and regulatory changes. Eli Lilly recently reported strong Q3 results, indicating long-term upside. Investors are advised to consider these stocks for potential investment opportunities.

    Market Beat·
    US
    NVO
    +1.01%
    US
    LLY
    +1.38%
    US
    ABBV
    +1.80%
    Market Beat·
    US
    NVO
    +1.01%
    US
    LLY
    +1.38%
    US
    ABBV
    +1.80%

    Promising Pharmaceutical Stocks Worth Watching - November 4th

    Eli Lilly, Pfizer, Novo Nordisk, 89BIO, and Metsera are highlighted as promising pharmaceutical stocks to watch, according to MarketBeat. These companies are involved in developing and marketing drugs and therapies, with their stock performance influenced by clinical trials and regulatory approvals. Eli Lilly has shown strong Q3 results, while Pfizer continues to expand its biopharmaceutical offerings. Novo Nordisk focuses on diabetes and obesity care, 89BIO targets liver diseases, and Metsera develops treatments for obesity. Investors are advised to monitor these stocks closely for potential opportunities.

    Market Beat·
    US
    NVO
    +1.01%
    US
    ETNB
    0.00%
    US
    LLY
    +1.38%
    Market Beat·
    US
    NVO
    +1.01%
    US
    ETNB
    0.00%
    US
    LLY
    +1.38%

    89BIO (NASDAQ:ETNB) Receives "Overweight" Rating from Cantor Fitzgerald

    Cantor Fitzgerald has reiterated an "overweight" rating on 89BIO (NASDAQ:ETNB) shares. Other analysts have mixed views, with Weiss Ratings giving a "sell (d-)" rating, Wolfe Research downgrading to "peer perform," and Zacks lowering to "strong sell." The stock remains flat at $14.84, with a consensus rating of "Hold" and a target price of $25.81. 89BIO reported a quarterly EPS of ($0.71), missing estimates. The company focuses on therapies for liver and cardio-metabolic diseases, with a market cap of $2.20 billion.

    Market Beat·
    US
    ETNB
    0.00%
    Market Beat·
    US
    ETNB
    0.00%

    Cantor Fitzgerald Remains a Buy on 89bio (ETNB)

    According to TipRanks, Seedhouse is a 4-star analyst with an average return of 11.5% and a 44.69% success rate. Seedhouse covers the Healthcare sector, focusing on stocks such as Astria Therapeutics, BioCryst, and Tvardi Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for 89bio with a $30.19 average price target.

    Tip Ranks·
    US
    ETNB
    0.00%
    Tip Ranks·
    US
    ETNB
    0.00%

    89bio Completes Merger and Delists from Nasdaq

    89bio has completed its merger, resulting in its delisting from Nasdaq and significant changes in its management structure. The company is now a wholly owned subsidiary of its parent company, with board members resigning. The latest analyst rating for ETNB stock is a Hold with a $14.50 price target. Spark's AI Analyst rates ETNB as Neutral, citing ongoing losses and cash flow issues, despite promising clinical progress. The stock is considered high-risk, high-reward, with a current market cap of $2.2B and an average trading volume of 5,392,262 shares.

    Tip Ranks·
    US
    ETNB
    0.00%
    Tip Ranks·
    US
    ETNB
    0.00%
    © 2025 Longbridge｜Disclaimer